NCI-H1975 Xenograft Model Service for NSCLC

The NCI-H1975 xenograft model stands as a cornerstone preclinical platform for investigating acquired EGFR-TKI resistance driven by the T790M gatekeeper mutation in non-small cell lung cancer (NSCLC), enabling researchers to evaluate next-generation therapeutic strategies, dissect resistance mechanisms, and assess combination regimens in a physiologically relevant immunodeficient host. Alfa Cytology delivers comprehensive NCI-H1975 xenograft model services supported by authenticated cell stocks, rigorous quality control, and customizable endpoint analyses to generate reproducible, publication-ready data that advance your preclinical oncology pipeline from target validation to lead optimization.

Overview of NCI-H1975 Xenograft Model for NSCLC

The NCI-H1975 cell line was established in 1988 from a lung adenocarcinoma specimen of a female patient who had never smoked. Genetically, this line harbors the EGFR L858R activating mutation in exon 21 together with the T790M gatekeeper mutation in exon 20—a double-mutation profile that confers intrinsic resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib, gefitinib, and afatinib, while remaining sensitive to third-generation mutant-selective inhibitors including osimertinib. This resistance-conferring genotype makes NCI-H1975 one of the most widely utilized preclinical models for studying T790M-mediated acquired resistance and for evaluating therapeutic strategies designed to overcome or bypass this critical resistance mechanism.

Fig 1. The H1975-OsiR osimertinib-resistant line exhibited a >190-fold IC50 shift (3765 vs 19.1 nM) versus parental NCI-H1975, providing a paired in vitro/in vivo model system for third-generation TKI resistance. (Meraz, Ismail M., et al., 2023)

In immunodeficient murine hosts, NCI-H1975 cells form reproducible subcutaneous tumors with consistent take rates and moderate-to-slow growth kinetics, supporting longitudinal tumor volume monitoring and pharmacodynamic sampling over extended treatment windows. The xenograft model has been extensively applied to assess the efficacy of third-generation EGFR-TKIs, combination regimens with MEK or PI3K pathway inhibitors, antibody-drug conjugates, and novel agents targeting compensatory resistance pathways. Endpoint tumor tissues are amenable to immunohistochemistry, Western blotting, RNA sequencing, and flow cytometric analysis, providing multi-layered mechanistic insights that bridge in vitro resistance findings to in vivo therapeutic outcomes.

Cell Line Information: NCI-H1975

NCI-H1975 is a human lung adenocarcinoma cell line with a distinctive EGFR L858R/T790M double-mutation profile, making it the archetypal model for studying acquired resistance to first- and second-generation EGFR-TKIs. Established from a primary tumor specimen, this line retains epithelial morphology and exhibits robust tumorigenicity in immunodeficient murine hosts. The table below summarizes the key biological and technical attributes of the NCI-H1975 cell line relevant to xenograft model development.

Our Services

Alfa Cytology offers end-to-end NCI-H1975 xenograft model services customized to your preclinical research objectives. Our scientific team manages every stage—from authenticated cell banking and mycoplasma screening to tumor establishment, randomized group allocation, compound administration, and comprehensive endpoint analysis—ensuring regulatory compliance, data integrity, and transparent reporting throughout your study.

Workflow of NCI-H1975 Xenograft Model Construction

Construction of the NCI-H1975 xenograft model follows a systematic, quality-controlled workflow designed to ensure reproducible tumor growth, ethical compliance, and robust data generation. Each stage is executed under GLP-aligned standard operating procedures with complete documentation and batch traceability from cell banking to final report delivery.

1. Cell Line Authentication and Expansion: NCI-H1975 cells are revived from authenticated cryopreserved master stocks and expanded under sterile conditions. Short tandem repeat (STR) profiling, mycoplasma testing, and viability assessment are performed to confirm identity and purity. The EGFR L858R/T790M mutation status is verified by targeted sequencing prior to inoculation.
2. Animal Preparation and Cohort Randomization: Immunodeficient mice are quarantined and acclimated for a minimum of five days under controlled environmental conditions. Animals are randomized into vehicle and treatment groups based on body weight, with all protocols approved by the institutional animal care and use committee (IACUC).
3. Tumor Cell Inoculation: A suspension of 1–5 × 10⁶ NCI-H1975 cells in 100 µL of ice-cold PBS/Matrigel (1:1) is injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle. Orthotopic lung implantation is available upon request for studies requiring organ-specific tumor microenvironment interactions.
4. Longitudinal Tumor Monitoring: Tumor dimensions are measured with digital calipers twice weekly beginning from the appearance of palpable masses. Tumor volume is calculated using the modified ellipsoid formula: length × (width)² / 2. Body weight and clinical observations are recorded concurrently to assess treatment tolerability.
5. Test Article Administration: Investigational compounds are administered according to the study-specific regimen via oral gavage, intraperitoneal, intravenous, or subcutaneous routes. Vehicle control groups receive the equivalent formulation without active agent. Combination arms and dose-escalation cohorts are configured as specified in the study protocol.
6. Endpoint Assessment and Tissue Collection: Mice are humanely euthanized upon reaching the predetermined endpoint—typically when tumor volume approaches 1,500 mm³ or at a fixed study duration. Tumors are excised, weighed, and subdivided for formalin-fixed paraffin-embedded (FFPE) histology, snap-frozen molecular analysis, and single-cell dissociation for flow cytometry.
7. Data Analysis and Study Reporting: Tumor growth curves, tumor growth inhibition (TGI) percentages, and statistical comparisons between treatment groups are generated using validated biostatistical platforms. A comprehensive study report including raw data, methodology, representative images, and mechanistic interpretation is delivered to the sponsor.

Fig 2. NCI-H1975 xenograft model construction workflow.

Case Study-NCI-H1975 Xenograft Model Development

In a recent preclinical engagement, the NCI-H1975 xenograft model was utilized to evaluate the anti-tumor efficacy of a third-generation EGFR-TKI in combination with a compensatory pathway inhibitor for T790M-positive NSCLC. Following subcutaneous inoculation of NCI-H1975 cells into athymic nude mice, measurable tumors were established within 28 days with a take rate exceeding 90%. Animals were randomized into vehicle, monotherapy, and combination treatment arms once mean tumor volume reached approximately 200 mm³. Longitudinal monitoring revealed dose-dependent tumor growth inhibition across treatment cohorts, with combination-treated groups demonstrating enhanced suppression compared to single-agent controls. Endpoint pharmacodynamic analysis showed marked reduction of phosphorylated EGFR and downstream effectors in tumor lysates from responder groups, alongside decreased Ki-67 proliferative indices. Histopathological examination confirmed preserved adenocarcinoma morphology with treatment-associated changes in tumor architecture. These preclinical findings supported the mechanistic rationale for advancing the therapeutic strategy into subsequent development stages.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your NCI-H1975 xenograft studies ensures access to a fully integrated preclinical infrastructure that combines scientific depth with operational excellence. Our service model is engineered to deliver actionable, high-fidelity data within competitive timelines.

• Authenticated cell repositories with routine STR profiling, mycoplasma screening, and EGFR mutation verification to ensure genetic fidelity throughout the study.
• Customizable study designs encompassing subcutaneous, orthotopic, and acquired-resistance model configurations tailored to your mechanistic questions.
• Real-time tumor growth tracking via digital calipers or optional non-invasive imaging modalities including bioluminescence and micro-CT upon request.
• Comprehensive endpoint analysis spanning histopathology, immunohistochemistry, Western blot, qPCR, RNA sequencing, and multiplex cytokine profiling.
• Dedicated project scientists providing weekly progress updates, direct raw data access, and regulatory-compliant documentation packages.
• Accelerated study timelines with standard tumor establishment and treatment phases typically completed within 6–8 weeks from project initiation.

Contact Us

Ready to overcome T790M-mediated resistance and advance your next-generation EGFR-targeted NSCLC research? Reach out to the Alfa Cytology scientific team today to discuss your study design, receive a customized proposal, and discover how our NCI-H1975 xenograft expertise can accelerate your preclinical pipeline. Contact us now to schedule a consultation and move your program forward with confidence.

For research use only. Not intended for any clinical use.